Enterprise Value
39.66M
Cash
317.2M
Avg Qtr Burn
-25.66M
Short % of Float
9.74%
Insider Ownership
22.29%
Institutional Own.
63.51%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Naporafenib (pan-RAF inhibitor) w/ trametinib Details NRASm melanoma, Melanoma | Phase 3 Initiation | |
Naporafenib (pan-RAF inhibitor) w/ trametinib Details Solid tumor/s, RAS Q61X solid tumors | Phase 1b Data readout | |
ERAS-601 (SHP2 inhibitor) Details Solid tumor/s, Cancer, Head and neck squamous cell carcinoma | Phase 1b Data readout | |
ERAS-007 Details Cancer, Gastrointestinal stromal tumors, Advanced malignancies, Colorectal cancer , BRAFm Colorectal Cancer | Phase 1b Data readout | |
ERAS-801/EGFR inhibitor Details Cancer, Glioblastoma | Phase 1 Data readout | |
ERAS-007 Details Non-small cell lung carcinoma | Failed Discontinued | |
ERAS-007 + ERAS-601 Details Solid tumor/s, Cancer | Failed Discontinued |